RERE-AS1 as a regulator of immune modulation and therapeutic response in breast cancer

Le résumé fourni par la source

BACKGROUND AND AIMS: Breast cancer (BRCA) remains one of the most prevalent malignancies and a major threat to women's health worldwide. The biological role and mechanistic basis of the long non-coding RNA (lncRNA) RERE-AS1 in BRCA remain unclear. METHODS: Clinical and RNA sequencing data from BRCA patients were analyzed to determine RERE-AS1 expression levels. RNA fluorescence in situ hybridization (FISH) was used to visualize its distribution in tumor tissues. Functional assays were conducted in MCF-7 and T47D cells to assess the effects of RERE-AS1 on cellular proliferation, migration, invasion, and apoptosis using Cell Counting Kit-8 (CCK-8), Transwell assays, and flow cytometry. Cell cycle progression was also evaluated. A co-culture system of BRCA cells and immune cells was established to examine immune cell migration, lactate dehydrogenase (LDH) release, and immune cytotoxicity. Cytokine secretion was quantified via enzyme-linked immunosorbent assay (ELISA). Furthermore, a xenograft mouse model was utilized to confirm the impact of RERE-AS1 on tumor growth and its response to anti-PD-1 therapy. RESULTS: RERE-AS1 expression was markedly decreased in BRCA tissues and correlated with overall survival (OS), tumor stage, and immune infiltration levels. Functional experiments demonstrated that RERE-AS1 overexpression inhibited BRCA cell proliferation, migration, and invasion while inducing apoptosis and cell cycle arrest. Additionally, RERE-AS1 strengthened the interaction between BRCA and immune cells, reduced immune escape, and enhanced tumor sensitivity to immune checkpoint blockade therapy. CONCLUSION: RERE-AS1 acts as a promising prognostic biomarker and potential therapeutic target in BRCA. Its expression is closely associated with disease progression and patient outcomes and plays a regulatory role in tumor cell behavior and immune microenvironment modulation. CLINICAL RELEVANCE STATEMENT: This study identifies RERE-AS1 as a critical regulator of tumor-immune interactions, suggesting its potential for guiding precision immunotherapy and prognostic assessment in BRCA patients.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.